Daniele Pieraccioli - MolMed S Insider

4HW -- Germany Stock  

EUR 0.30  0.015  4.70%

  Director
Dr. Daniele Pieraccioli Ph.D. serves as Director of Intellectual Property at Molecular Medicine S.p.A. since December 2007. He is Qualified European Patent Attorney with scientific background in Medicinal Chemistry and Biotechnology and is responsible for managing all aspects of intellectual property including evaluation of patentability patent prosecution and freedom to operate through validityinfringement opinions. He has international experience with pharmaceutical and biotech companies including GlaxoSmithKline and Serono. He was Research Scientist for a few years before his professional involvement in the intellectual property. He was involved in the patentee side in patent infringement proceedings on blockbuster drugs as well as in EPO proceedings and litigations in Europe on biotechnological products with final positive outcome of the proceedings. He is Speaker at both national and international Conferences and Author of publications in the field of Intellectual Property. He gained a degree in Chemistry from Universita degli Studi di Firenze and gained a Doctorate in Philosophy from Eidgenossische Technische Hochschule Zurich.
Age: 65  Director Since 2007  Ph.D    
39 02 21 27 71  http://www.molmed.com

Management Efficiency

The company has return on total asset (ROA) of (11.32) % which means that it has lost $11.32 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (25.93) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 3.9 implying the company greatly relies on financing operations through barroing. MolMed S p A has Current Ratio of 1.94 which is within standard range for the sector.

Similar Executives

Entity Summary

MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. MolMed S.p.A. was founded in 1996 and is headquartered in Milan, Italy. MolMed S operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange.MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. It is located in Via Olgettina, 58 and employs 23 people.

MolMed S p Leadership Team

Gian Rizzardi, Director Research & Development
Marina Bue, General Manager of Business Development and Administration, Executive Director
Didier Trono, Independent Director
Silvia Pisante, Head of Legal Affairs & Corporate Governance
Mario Masciocchi, Lead Independent Director
Carlo Incerti, Independent Director
Raffaella Ruggiero, Independent Director
Holger Neecke, Director Business Development & Investor Relations
Luca Alberici, Head of Business Development
Maurizio Tassi, Non-Executive Director
Daniele Pieraccioli, Director Intellectual Property
Alberto Carletti, Non-Executive Director
Laura Ferro, Independent Director
Marco Dieci, Director Special Projects
Catia Traversari, Director Research
Lorenzo Salieri, Director
Elizabeth Robinson, Independent Director
Riccardo Palmisano, CEO
Sabina Grossi, Non-Executive Director
Alfredo Messina, Non-Executive Director
Monica Masolo, Independent Director
Germano Carganico, General Manager of Research & Development and Operations
Claudio Bordignon, Chairman of the Board, CEO
Gianluigi Fiorendi, Non-Independent Non-Executive Director
Andrea Quaglino, Director Administration Finance & Control
Khalid Islam, Non-Executive Non-Independent Director
Laura Villa, Director of Investor Relations & Communication
Cynthia Giuliani, Director of Human Resources
Antonio Lambiase, Director Clinical Development
Marco Manoni, Director Operations
Tiziano Andreoli, Director of Information Technology

Stock Performance Indicators

Current Sentiment - 4HW

MolMed S p Investor Sentiment

Macroaxis portfolio users are unresponsive in their sentiment towards investing in MolMed S p A. What is your trading attitude regarding investing in MolMed S p A? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Thematic Ideas
Explore Investing Ideas  
Check also Trending Equities. Please also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Search macroaxis.com